zelicapavir

Small molecule

Negativelead readout

Evidence outlook · lead readout

RSVHR (NCT05568706) · Respiratory Syncytial Virus Infection

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

RSVHR (NCT05568706): RSVHR was a randomized, double-blind, placebo-controlled Phase 2b trial in 186 non-hospitalized adults with RSV at high risk of complications, given zelicapavir 800 mg (n=121) or placebo (n=65) once daily for 5 days. The sponsor states that no effect was seen on the primary endpoint, time to resolution of the four lower respiratory tract symptoms to mild, so the primary was missed. The sponsor reports faster resolution on secondary and subgroup measures (HR3 population), but those are not the primary. Source: the sponsor's topline release filed with the SEC (8-K exhibit 99.1, 29 Sep 2025) and CT.gov posted results.

Result from the sponsor's press release and CT.gov posted medians; no peer-reviewed publication was found.

Company guidance: topline data expected 1Q 2027 (Enanta Pharmaceuticals, Inc., 16 Nov 2026). “Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027” Source ↗

Company guidance: data expected in 2027 (NCT07908381; Enanta Pharmaceuticals, Inc., 16 Nov 2026). “We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said Jay R.” Source ↗

Company guidance: topline data expected in 2027 (NCT07908381; Enanta Pharmaceuticals, Inc., 18 Nov 2026). “Topline data from the Phase 2b portion of RESOLVE are expected in 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
NCT07908381 · Enanta Pharmaceuticals, Inc
2026-10-19 – 2029-07 · RSV
What this study did
Phase 2 (6)
Respiratory Syncytial Virus Infection
Other / comorbidity
NCT07482657 · Enanta Pharmaceuticals, Inc
2026-07-09 – 2026-12 · RSV Infection, RSV, Respiratory Syncytial Virus (RSV)
What this study did
NCT04816721 · Enanta Pharmaceuticals, Inc
2022-04-26 – 2024-08-19 · Respiratory Syncytial Virus (RSV)
What this study did
NCT04196101 · Enanta Pharmaceuticals, Inc
2020-01-22 – 2022-01-04 · Respiratory Syncytial Virus
What this study did
NCT03691623 · Enanta Pharmaceuticals, Inc
2018-10-15 – 2019-10-18 · RSV Infection
What this study did
Phase 1 (7)
Other / comorbidity
NCT06601192 · Enanta Pharmaceuticals, Inc
2024-07-15 – 2025-02-25 · RSV Infection, QTc Interval
What this study did
NCT04927793 · Enanta Pharmaceuticals, Inc
2021-05-28 – 2021-07-04 · Respiratory Syncytial Virus (RSV)
What this study did
NCT04498741 · Enanta Pharmaceuticals, Inc
2020-07-08 – 2021-06-01 · RSV Infection
What this study did
NCT04871724 · Enanta Pharmaceuticals, Inc
2021-03-12 – 2021-04-16 · RSV Infection
What this study did
NCT03755778 · Enanta Pharmaceuticals, Inc
2018-11-29 – 2019-01-27 · RSV Infection
What this study did
NCT03384823 · Enanta Pharmaceuticals, Inc
2017-12-07 – 2018-07-03 · RSV Infection
What this study did

Competitive landscape

This drug's own stage for Respiratory Syncytial Virus Infection: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zelicapavir: this drugPhase 2Small moleculeRSV N protein (nucleoprotein)Weak signal
NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed
NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants
Clesrovimab (Enflonsia)ApprovedMonoclonal antibodyRSV F proteinnot yet gradedNo reviewed efficacy summary in this indication
mRESVIAApprovedVaccineRSV pre-F proteinPartial signal
NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses).
EDP-323Phase 2Small moleculeRSV L proteinPartial signal
NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743)
GSK5893818
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0256
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0291
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0340
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0341
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow zelicapavir to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2RSV Infection, RSV, Respiratory Syncytial Virus (RSV)Recruiting
Est. primary completion 2026-12 · NCT07482657 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2/3RSVRecruiting
Est. primary completion 2029-07 · NCT07908381 · CT.gov ↗

Company guidance: data expected in 2027 (Enanta Pharmaceuticals, Inc., 16 Nov 2026). “We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said Jay R.” Source ↗

Company guidance: topline data expected in 2027 (Enanta Pharmaceuticals, Inc., 18 Nov 2026). “Topline data from the Phase 2b portion of RESOLVE are expected in 2027.” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 September 2025Topline resultPhase 2b RSVHR of zelicapavir: no effect on the primary symptom endpoint; key secondary virology endpoints met
Enanta Pharmaceuticals, Inc. · Source ↗